Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talaporfin sodium photodynamic therapy for pediatric malignant brain tumors
jRCTs031180360Phase 2Completed
- Start
- Jun 2018
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talaporfin sodium in brain neoplasm. Primary endpoints: Safety and Overall survival rate at 12 months after PDT. Started Jun 2018; status: completed.
02
Drugs
talaporfin sodium
03
Conditions
brain neoplasm
Beyond the preview
Go deeper on jRCTs031180360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180360.